3M Completes Sale of its Pharmaceuticals Business in Asia Pacific Region
Advertisement
3M announced it has completed its transaction with Ironbridge Capital and Archer Capital to sell 3M's pharmaceutical operations in the Asia Pacific region, including Australia and South Africa, for $349 million.
The new dedicated pharmaceuticals company will be headquartered in Sydney, Australia under the leadership of Tony Martin, formerly general manager of 3M Pharmaceuticals' Asia Pacific operations. The acquisition includes leading products in both over-the-counter and prescription medicines, such as Difflam, Duro-Tuss, Aldara, Tambocor and Duromine.
The transactions with Graceway Pharmaceuticals Inc. for the sale of 3M's pharmaceuticals operations in the U.S., Canada, and Latin America; and Meda AB for the sale of 3M's pharmaceuticals business in Europe, are expected to close within the next 30 days subject to customary closing conditions including regulatory approvals, and in the case of Graceway Pharmaceuticals, the receipt of financing.
Most read news
Other news from the department business & finance
Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.